 |
| Keystone Heart's TriGuard cerebral protection device |
Israel-based medical device maker Keystone Heart raised $14 million in Series B cash it will use for continued studies of its cerebral protection product used in transcatheter aortic valve replacement (TAVR) procedures.
The financing was led by OrbiMed and the money will be used to conduct clinical trials in Europe for its CE-marked TriGuard device, and for a planned FDA Investigational Device Exemption (IDE) study, the company said in a release.
The company also announced that Hank Hauser has joined Keystone as vice president of its clinical operations.
Keystone claims TriGuard is the only cerebral protection device specifically designed to provide full coverage to all aortic arch takeoffs, and minimizes the risk of cerebral damage during TAVR and other cardiovascular procedures.
Boston Scientific ($BSX), a major player in the TAVR field, recently presented favorable clinical trial results for its Lotus device. Medtronic ($MDT), having won a major battle last month in its ongoing TAVR patent war with Edwards Lifesciences ($EW) that warded off an injunction that would have prevented it from marketing CoreValve in the U.S., released new data from a study showing that its CoreValve system was effective in treating high-risk patients.
- read the release